Servier unveils new production unit in France

French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines.

Venous diseases are among the most common diseases in the world, affecting around 30% of the world’s population, or 2.2 billion patients.Furthermore, the incidence of venous diseases is increasing by 4% each year, with the highest prevalence in Eastern Europe and Latin America (nearly 70%). Current estimates indicate that the number of patients still untreated exceeds 30%.

Therefore, with a view to fulfilling the growing need for therapeutic solutions in the treatment of venous diseases, we have invested 150 million euros ($162 million) to develop a new manufacturing process and build a new production unit. Part of the investment was dedicated to the construction of a methanization plant to recycle processed waste into gas, thus enabling the unit to be nearly self-sufficient in terms of energy requirements. In addition, an effluent treatment plant was installed to reduce the site’s environmental footprint through a greener, cleaner, and more autonomous treatment cycle.